* Axcella Health Inc AXLA.OQ AXLA.O is expected to show
no
change in quarterly revenue when it reports results on March
30.
* Refinitiv's mean analyst estimate for Axcella Health Inc
is for
a loss of 44 cents per share. For the same quarter last year,
the company reported a loss of 40 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Axcella
Health
Inc is $12, above its last closing price of $2.82.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.45 -0.46 -0.41 Beat 10.5
Jun. 30 2021 -0.41 -0.43 -0.42 Beat 1.8
Mar. 31 2021 -0.42 -0.42 -0.40 Beat 4
Dec. 31 2020 -0.32 -0.36 -0.40 Missed -10.8
Sep. -0.39 -0.41 -0.34 Beat 16.6
30 2020
Jun. 30 2020 -0.53 -0.56 -0.48 Beat 14.6
Mar. 31 2020 -0.84 -0.86 -0.65 Beat 24.2
Dec. 31 2019 -0.74 -0.68 Beat 7.7
This summary was machine generated March 28 at 12:44 GMT. All
figures in US dollars unless otherwise stated